Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
SNT Stock Chart & Stats
AU$0.03
>-AU$0.01(-6.33%)
At close: 4:00 PM EST
AU$0.03
>-AU$0.01(-6.33%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.09
Previous CloseN/A
Volume5.35M
Average Volume (3M)3.71M
Market Cap
AU$50.66M
Enterprise ValueAU$34.03M
Total Cash (Recent Filing)AU$7.14M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.87
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,634,088,700
10 Day Avg. Volume2,483,870
30 Day Avg. Volume3,709,067
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$28.25M
Syntara Limited News
SNT FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest share price was AU$0.02 and its highest was AU$0.09 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is AU$50.66M.
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 177 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Feb 06, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Overvalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,634,088,700 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in AU:SNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syntara Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:SNT Sentiment 93%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.04%
12-Months-Change
Fundamentals
Return on Equity
-118.44%
Trailing 12-Months
Asset Growth
106.56%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates that target fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Technical Analysis
Alterity Therapeutics
―
Genetic Signatures Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
PainChek Ltd
―
Options Prices
Currently, No data available
---